• Cancel
    Date：2022-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=729

    Therorna Inc. is dedicated to the development of novel vaccines and therapies in multiple cutting-edge treatment areas, focusing on international frontier circular RNA (circRNA) technology. This funding round was led by MSA Capital and a renowned industri

  • Cancel
    Date：2022-06

    Exclusive Financial Advisor to the founders of Taikang Bybo Dental

  • Cancel
    Date：2022-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=730

    Sihuan Pharm announced that its non-wholly-owned subsidiary, Huisheng Pharm, has completed a RMB 500 million Series A financing. This round was invested by China Life Chengda (Shanghai) Health Industry Equity Investment Centre (L.P.), GF Investment, GF In

  • Cancel
    Date：2022-05
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=731

    Senlang Biotechnology announced the successful closing of RMB 200 million from Qianhai Ark Asset Management. CEC Capital Group acted as the exclusive financial advisor for Senlang Biotechnology in this transaction.

  • Cancel
    Date：2022-05

    Exclusive Financial Advisor to DOBOSO

  • Cancel
    Date：2022-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=732

    Fosun Pharmaceutical recently announced that its subsidiary, YanengBIO, along with its existing shareholders, has entered into a relevant agreement with Yaneng Bioscience under CBridge Capital. Upon completion of the transaction, YanengBIO will transition

  • Cancel
    Date：2022-04
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=733

    Yunsilicon announced the acquisition of another hundred million RMB in investment. This round was led by Lightspeed China Partners, with strategic investment from MorethanMoore, a subsidiary fund under the National IC Industry Investment Fund, and partici

  • Cancel
    Date：2022-03
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=734

    DataMesh, the digital twin platform provider, has recently achieved a successful completion of its B2 round financing. The funds secured in this round are predominantly designated for the development of enterprise metaverse products and the expansion into

  • Cancel
    Date：2022-02

    Exclusive Financial Advisor to DECANS